Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grass MATA MPL dose-finding in seasonal allergic rhinoconjunctivitis
NCT02582073Phase 2Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Grass MATA MPL in seasonal allergic rhinitis (SAR) (6 arms), sponsored by Allergy Therapeutics PLC. Primary endpoint: Total Symptom Score. Started Nov 2015; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02582073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582073.